Antineoplastic - Phosphatidylinositol 3-Kinase Delta Inhib.

Antineoplastic phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors are a targeted antineoplastic drug class that selectively blocks the p110δ catalytic isoform of PI3K, an enzyme predominantly expressed in hematopoietic cells

Antineoplastic phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors are a targeted antineoplastic drug class that selectively blocks the p110δ catalytic isoform of PI3K, an enzyme predominantly expressed in hematopoietic cells The class has primarily been developed and utilized for hematologic malignancies, most notably relapsed or refractory indolent B-cell neoplasms such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma

By disrupting downstream intracellular signaling cascades—principally the PI3K/Akt pathway—these agents inhibit malignant B-cell proliferation, impair survival signaling, and promote apoptosis

By disrupting downstream intracellular signaling cascades—principally the PI3K/Akt pathway—these agents inhibit malignant B-cell proliferation, impair survival signaling, and promote apoptosis

The class has primarily been developed and utilized for hematologic malignancies, most notably relapsed or refractory indolent B-cell neoplasms such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma